-
Safety of Monitoring During Use of Ozempic in People with Diabetes
This project aims to conduct a cohort study in 4 Canadian provinces to demonstrate the feasibility of replicating a US FDA Sentinel TreeScan signal-detection analysis using Ozempic as the case study.
OS0005_CDMExploration of the Risk of Suicidality and Self-Harm With GLP-1 Receptor Agonists: A Critical Appraisal
This project is a critical appraisal of the available real-world evidence to evaluate the association between GLP-1 RAs and the risk of suicidality and self-harm among patients with type 2 diabetes or obesity.
HC0087Outpatient Nirmatrelvir-Ritonavir and Remdesivir Utilization in Canada
The purpose of this study is to describe the use of nirmaltrelvir-ritonavir and remdesivir in the outpatient setting across Canadian provinces for which data are readily available, and describe the characteristics of patients receiving these therapies. This project is a collaboration with ADTEC and INESSS.
HC0069Utilization Analysis of Tofacitinib and Other Drugs Among Individuals with Ulcerative Colitis: Feasibility Analysis
There is limited evidence on the safety of tofacitinib in patients with ulcerative colitis. The objective of this study is to describe the use of tofacitinib and other therapies among individuals diagnosed with ulcerative colitis and determine the feasibility of a comparative safety study of MACE, hospitalized thrombotic events, and cancer.
OS0003Risk of Arterial and Venous Thrombotic Events Among Patients with COVID-19: A Multi-National Collaboration of Regulatory Agencies from Canada, Europe, and United States
The risk of arterial thromboembolism and venous thromboembolism among patients diagnosed with COVID-19 varied by country. This variation was observed among patients initially diagnosed in the ambulatory setting and the hospital setting, and before and during COVID-19 vaccine availability. Differences in healthcare systems, data sources, prevalence of underlying comorbid conditions, and approaches to COVID-19 and thromboembolism case definition may have contributed to the variation in thromboembolism risk estimates observed between countries.
Q20-21_CDMPrescription ranitidine use and population exposure in 6 Canadian provinces, 1996 to 2019: a serial cross-sectional analysis
In September 2019, Health Canada directed domestic manufacturers to cease distributing ranitidine due to potentially high concentrations of the possible carcinogen N-nitrosodimethylamine (NDMA). This study will characterize the use of dispensed histamine-2 receptor antagonists (H2RAs) in Canada by describing demographic and clinical characteristics of users and prescribers.